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Background: We examined the association between liver enzymes and development of type 2 diabetes in a
general Korean population.
Methods: A total of 10,667 subjects (4,201 males and 6,466 females) aged 45 to 74 years participated in a baseline
examination between 2004 and 2007. Among the subjects, 8,157 (3,231 males and 4,926 females) underwent
follow-up examination from 2007 to 2011, for a median follow-up period of 4.2 years. Type 2 diabetes was defined
as intake of anti-diabetic agents, insulin treatment, fasting glucose concentration of more than 126 mg/dl, or
hemoglobin A1c of more than 6.5% at re-examination. Associations of liver enzymes with incidence of type 2
diabetes were analyzed using logistic regression models.
Results: During the follow-up period, 548 subjects (235 males, 313 females) developed type 2 diabetes. After
adjusting for comprehensive diabetes risk factor, the risk of type 2 diabetes was significantly higher in the highest
alanine aminotransferase (ALT) quartile than in the lowest quartile (odds ratio (OR): 1.95, 95% confidence interval
(CI): 1.18-3.21 in males; OR: 1.49, 95% CI: 1.03-2.16 in females). Similar results were observed for gamma-
glutamyltransferase (GGT) quartiles, but in the fully adjusted analysis, the OR for the highest versus lowest quartiles
was significant only for females (OR: 1.58, 95% CI: 0.95-2.63 in males; OR: 1.85, 95% CI: 1.23-2.79 in females).
Conclusions: Our results suggest that serum ALT concentrations were independently associated with type 2
diabetes in both sexes, and that GGT was also independently associated but only in females.
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The liver plays an important role in maintenance of nor-
mal glucose levels during fasting as well as in the post-
prandial period [1], and its role in the pathogenesis of
type 2 diabetes has attracted much interest. Indeed,
hepatic dysfunction resulting from insulin-resistance syn-
drome may lead to development of type 2 diabetes [2].
The liver enzymes, aspartate aminotransferase
(AST), alanine aminotransferase (ALT), and gamma-
glutamyltransferase (GGT), are routinely used in evalu-
ation of liver function. Aspartate aminotransferase (AST)
and ALT are considered markers of hepatocellular health,
whereas GGT also indicates biliary tract function. Alanine* Correspondence: ujingogo@paran.com
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stated.aminotransferase (ALT) is the most specific marker of
liver pathology and is found primarily in this organ [3].
AST and GGT are also found in other tissues and are
therefore less specific markers of liver function [4]. Al-
though GGT is a less specific marker of liver function,
higher GGT levels have been found to be an independent
predictor of the incidence of type 2 diabetes.
A number of prospective studies have examined the
associations between concentrations of AST [5-12], ALT
[5-11,13,14], or GGT [3,4,6-11,14-21] and the incidence
of type 2 diabetes. A few studies have examined the as-
sociation of serum AST with risk for type 2 diabetes;
two of these reported a significant association between
serum AST and diabetes after adjustment for potential
confounders [5,9]. Most previous studies examining the
association between liver enzymes and incidence of type
2 diabetes have included only ALT or GGT. A limited. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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ations of AST, ALT, and GGT with risk of type 2 dia-
betes [6-14]; however, the results were inconsistent.
The purpose of this study was to examine the associa-
tions of serum liver enzyme (AST, ALT, and GGT) levels
on the incidence of type 2 diabetes in a community-
based prospective cohort study of Korean individuals
aged 45 to 74 years.
Methods
Study population
Data were derived from the Namwon Study [22]. The
Namwon Study is a prospective, population-based cohort
study conducted in the city of Namwon, Jeollabukdo,
Korea. The study targets cardiovascular disease, osteo-
porosis, and dementia in elderly Koreans. The 2005
population census performed by the Korean National
Statistics Office reported 33,068 residents (14,960 males
and 18,108 females) aged 45–74 in Namwon city. From
2004 to 2007, all eligible residents aged 45–74 were in-
vited to participate by mail and telephone, based on the
list of officially registered residents. A total of 10,667 sub-
jects (4,201 males and 6,466 females; response rate
32.3%) underwent clinical examinations following ques-
tionnaire interviews.
Of the 10,667 subjects, 8,157 (3,231 males and 4,926
females; response rate 76.6%) participated in follow-up
examinations between 2007 and 2011. Follow-up exami-
nations were conducted using the same protocol as the
baseline study. Of these 8,157 subjects, 1,231 (15.1%)
were excluded: 935 (11.5%) subjects with type 2 diabetes
at baseline examination; 146 (1.8%) subjects who were
diagnosed by physicians with chronic hepatitis B or C,
liver cirrhosis, or liver cancer; 89 (1.1%) subjects with in-
complete data on any of the covariables; and 61 (0.7%)
subjects without a blood sample at baseline or follow-
up examination. Finally, the prospective analysis in-
cluded 6,926 subjects (2,603 males and 4,323 females)
aged 45–74 years at baseline examination. Incidence of
type 2 diabetes was identified as intake of anti-diabetic
agents, receiving insulin treatment, fasting glucose
levels ≥126 mg/dl, or hemoglobin A1c levels ≥6.5% at
follow-up examination.
Baseline assessment
All subjects underwent a clinical examination and an-
swered a questionnaire, which included questions on life-
style, medical history (including diabetes, hypertension,
and other chronic diseases), and medical treatment with
insulin and oral anti-diabetic agents.
Subjects were classified into three groups according to
their alcohol intake status: nondrinkers, ex-drinkers, and
current drinkers. Subjects were characterized on the basis
of smoking status as never smokers, ex-smokers, andcurrent smokers. Physical activity was classified into two
categories according to whether subjects reported en-
gaging in any physical activity, such as jogging, bicycling,
swimming, or climbing.
Trained medical personnel performed anthropometric
measurements. Body mass index (BMI), calculated as
weight divided by the squared height in meters, was used
as an index of relative weight. Waist circumference (WC)
was measured to the nearest 0.1 cm using a tapeline.
Blood samples were obtained from an antecubital vein in
the morning after a 12-h overnight fast. Serum was sepa-
rated on site within 30 min and was stored at − 70°C until
analysis. AST, ALT, GGT, total cholesterol (TC), high-
density lipoprotein cholesterol (HDL-C), and triglycer-
ides (TG) levels were measured by an automatic analyzer
(HITACHI-7600, Hitachi, Japan). The HbA1c levels were
analyzed by high-performance liquid chromatography
(HPLC) using the VARIANT II system (Bio-Rad,
Hercules, CA, USA). Serum C-reactive protein (CRP)
was measured by latex-enhanced nephelometry by high-
sensitivity assays on the Behring Nephelometer II
analyzer (Dade-Behring Diagnostics, Marburg, Germany).
The index of insulin resistance was calculated on the
basis of fasting values of plasma glucose and insulin, ac-
cording to the homeostasis model assessment (HOMA)
method [23], as insulin resistance (%) = [insulin (units/
ml) × fasting glucose (mmol/l)]/22.5. All subjects had
provided written informed consent for participation in
the study. The Chonnam National University Hospital
Institutional Review Board approved this study.
Statistical analyses
The period of time before the follow-up examination
was calculated as the interval between the baseline
examination and re-examination. Baseline data are pre-
sented as means ± standard deviation (SD) or percent-
ages for categorical variables according to diabetes status
at follow-up. Baseline differences in general and bio-
chemical variables were compared using the t-test
(Mann–Whitney U test for AST, ALT, GGT, TG and
CRP) or chi-square test for categorical variables. Associ-
ations of liver enzymes with the incidence of type 2 dia-
betes were analyzed using logistic regression models.
Analyses were performed separately for males and fe-
males. The levels of liver enzymes were divided into four
groups, using sex-specific 25th, 50th, and 75th percen-
tiles as cut-points: for AST, 21, 25, and 31 U/L in males
and 19, 22, and 26 U/L in females; for ALT, 16, 21, and
30 U/L in males and 14, 17, and 22 U/L in females; for
GGT, 20, 31, and 55 U/L in males and 13, 16, and 22 U/
L in females. Four models were constructed for each
liver enzyme: the first model included age; the second
model included all previous factors plus BMI, WC, TC,
HDL-C, log TG, alcohol intake status, smoking status,
Table 2 Baseline characteristics of females subjects
Variables Females (n = 4,323)
Diabetes ‡ Non-diabetes p-value*
Age (years) 61.7 (6.9) 60.8 (7.7) 0.049
Body mass index (kg/m2) 26.1 (3.9) 24.5 (3.2) <0.001
Waist circumference (cm) 89.3 (8.7) 85.8 (8.7) <0.001
AST (units/l) 23 (19–27) 22 (19–26) 0.076
ALT (units/l) 20 (14–26) 16 (13–21) <0.001
GGT (units/l) 20 (15–31) 15 (12–21) <0.001
Fasting glucose (mg/dl) 106.8 (9.6) 96.5 (9.2) <0.001
HOMA (%) 1.74 (1.05) 1.31 (0.96) <0.001
Total cholesterol (mg/dl) 200.2 (36.2) 192.9 (36.7) 0.001
HDL cholesterol (mg/dl) 45.8 (10.9) 48.6 (11.7) <0.001
Triglycerides (mg/dl) 161 (113–243.5) 123 (86–177) <0.001
C-reactive protein (mg/dl) 0.09 (0.04-0.20) 0.05 (0.02-0.11) 0.444
Current drinker (%) 109 (34.8) 1,454 (36.3) 0.112
Current smoker (%) 11 (3.5) 110 (2.7) 0.317
Physical exercise (%) 100 (31.9) 1,242 (31.0) 0.730
Data are means (SD), medians (interquartile ranges; 25th-75th) for skewed
variables, or proportions for categorical variables. *Differences were assessed
using t-tests (for continuous variables) or chi-square tests (for categorical
variables); Mann–Whitney tests were performed for the following skewed
variables: AST, ALT, GGT, triglycerides and c-reactive protein.
‡ Diabetes status at follow-up examination.
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included all previous factors plus log CRP; and the
fourth model included all previous factors plus fasting
glucose and the HOMA value. Because the distributions
of AST, ALT, GGT, TG and CRP were skewed, we log-
transformed these values prior to inclusion in a logistic
regression model. Interactions of ALT and GGT with
BMI, WC, and alcohol intake status were estimated
using a logistic regression model. Linear trends were
evaluated using logistic regression with the AST, ALT,
and GGT categories as continuous variables. Results are
presented as odds ratios (ORs) and 95% confidence in-
tervals (CIs). A value of p <0.05 was taken to indicate
statistical significance. All statistical analyses were per-
formed using PASW statistics 21 (SPSS Inc., Chicago,
IL, USA).
Results
Baseline characteristics of subjects
Baseline characteristics of the study population accord-
ing to incident diabetes status at the follow-up examin-
ation are shown in Tables 1 and 2. During the median
follow-up period of 4.2 years (range 3.5 to 8.0 years),
548 subjects (235 males and 313 females) were newly
identified as having type 2 diabetes.
Compared to subjects who did not develop diabetes,
subjects of both sexes who developed type 2 diabetes
had higher BMI and WC; higher concentrations of ALT,Table 1 Baseline characteristics of males subjects
Variables Males (n = 2,603)
Diabetes ‡ Non-diabetes p-value*
Age (years) 62.4 (7.8) 62.4 (7.5) 0.848
Body mass index (kg/m2) 24.6 (2.9) 23.7 (2.7) <0.001
Waist circumference (cm) 87.1 (7.6) 84.7 (7.6) <0.001
AST (units/l) 26 (21–32) 25 (21–30) 0.089
ALT (units/l) 24 (18–34) 21 (16–29) <0.001
GGT (units/l) 39 (24–74) 30 (19–53) 0.006
Fasting glucose (mg/dl) 108.3 (13.8) 100.1 (9.7) <0.001
HOMA (%) 1.54 (1.10) 1.14 (1.13) <0.001
Total cholesterol (mg/dl) 183.6 (35.9) 182.8 (34.1) 0.658
HDL cholesterol (mg/dl) 45.5 (11.7) 47.2 (12.3) 0.045
Triglycerides (mg/dl) 152 (107–231) 128 (88–194) 0.002
C-reactive protein (mg/dl) 0.08 (0.04-0.17) 0.07 (0.03-0.16) 0.757
Current drinker (%) 151 (64.3) 1,577 (66.7) 0.490
Current smoker (%) 81 (34.5) 748 (31.6) 0.548
Physical exercise (%) 87 (37.0) 819 (34.7) 0.474
Data are means (SD), medians (interquartile ranges; 25th-75th) for skewed
variables, or proportions for categorical variables. *Differences were assessed
using t-tests (for continuous variables) or chi-square tests (for categorical
variables); Mann–Whitney tests were performed for the following skewed
variables: AST, ALT, GGT, triglycerides and c-reactive protein.
‡ Diabetes status at follow-up examination.GGT; higher fasting glucose levels, HOMA indices, and
TG; and lower levels of HDL-C. Although levels of liver
enzymes were within the normal range, subjects of both
sexes who developed type 2 diabetes had higher concen-
trations of ALT, and GGT than subjects who did not de-
velop diabetes. AST and CRP were slightly higher in
those of both sexes with diabetes; however, the differ-
ence was not significant in either sex.
AST and incidence of type 2 diabetes
There was no linear relationship between AST and inci-
dence of type 2 diabetes. The ORs for incidence of dia-
betes according to AST quartile were 0.98 (0.63-1.52),
0.93 (0.61-1.43), and 1.07 (0.69-1.66) in males and 0.67
(0.45-0.99), 0.83 (0.57-1.12), and 0.95 (0.66-1.37) in fe-
males after adjusting for age, BMI, WC, TC, HDL-C,
log-TG, alcohol intake status, smoking status, physical
activity, follow-up period, log-CRP, fasting glucose, and
HOMA indices (Tables 3 and 4).
ALT and incidence of type 2 diabetes
After adjusting for age, BMI, WC, TC, HDL-C, log-TG,
alcohol intake status, smoking status, physical activity,
follow-up period, and log-CRP, the ORs for incidence of
diabetes according to ALT quartile were 1.53, 2.24, and
2.31 in males and 0.97, 1.38, and 1.86 in females
(Tables 3 and 4). Further adjustment for fasting glucose
and HOMA indices attenuated the association; however,
Table 3 Adjusted odds ratio (95% confidence interval) for 4-years incidence of type 2 diabetes according to quartile
groups of liver enzymes (AST, ALT, and GGT) at baseline in males
Q1 Q2 Q3 Q4 P for trend
AST (units/l) ≤20 21 to 24 25 to 30 ≥31
Cases/persons at risk 49/620 56/656 64/687 66/640
Model 1 1 1.09 (0.73-1.62) 1.20 (0.81-1.77) 1.34 (0.91-1.98) 0.116
Model 2 1 1.11 (0.74-1.66) 1.10 (0.74-1.65) 1.21 (0.80-1.83) 0.390
Model 3 1 1.12 (0.73-1.71) 1.09 (0.72-1.65) 1.15 (0.76-1.76) 0.565
Model 4 1 0.98 (0.63-1.52) 0.93 (0.61-1.43) 1.07 (0.69-1.66) 0.794
ALT (units/l) ≤15 16 to 20 21 to 29 ≥30
Cases/persons at risk 31/615 46/632 81/710 77/646
Model 1 1 1.49 (0.93-2.39) 2.49 (1.62-3.83) 2.67 (1.72-4.15) <0.001
Model 2 1 1.42 (0.89-2.28) 2.19 (1.41-3.41) 2.11 (1.33-3.35) <0.001
Model 3 1 1.53 (0.93-2.52) 2.24 (1.40-3.59) 2.31 (1.42-3.75) <0.001
Model 4 1 1.36 (0.82-2.27) 2.03 (1.26-3.29) 1.95 (1.18-3.21) 0.004
GGT (units/l) ≤19 20 to 30 31 to 54 ≥55
Cases/persons at risk 38/661 44/651 72/635 81/656
Model 1 1 1.20 (0.77-1.89) 2.14 (1.42-3.23) 2.38 (1.59-3.57) <0.001
Model 2 1 1.09 (0.69-1.73) 2.00 (1.28-3.12) 2.13 (1.33-3.41) <0.001
Model 3 1 1.00 (0.62-1.63) 1.86 (1.17-2.96) 1.97 (1.21-3.22) 0.001
Model 4 1 0.86 (0.52-1.42) 1.57 (0.97-2.54) 1.58 (0.95-2.63) 0.011
Model 1: adjusted for age.
Model 2: Model 1 plus body mass index, waist circumference, total cholesterol, HDL-cholesterol, log-triglyceride, alcohol intake status, smoking status, physical
activity, and follow-up period.
Model 3: Model 2 plus log-CRP.
Model 4: Model 3 plus fasting glucose and HOMA.
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Comparison of the highest versus the lowest quartiles
for ALT showed ORs for incidence of type 2 diabetes of
1.95 (95% CI: 1.18-3.21) in males and 1.49 (95% CI: 1.03-
2.16) in females. Interactions of ALT with alcohol intake
status, BMI and WC were not significant in either sex
(data not shown).
GGT and incidence of type 2 diabetes
According to all models, there was a positive linear rela-
tionship between GGT and incidence of type 2 diabetes
in both sexes (Tables 3 and 4). After adjusting for age,
BMI, WC, TC, HCL-C, log-TG, alcohol intake status,
smoking status, physical activity, follow-up period, and
log-CRP, the ORs for incidence of diabetes according to
GGT quartile were 1.00, 1.86, and 1.97 in males and
1.11, 1.60, and 2.45 in females (Tables 3 and 4). Further
adjustment for fasting glucose and HOMA indices atten-
uated the association; however, GGT remained a signifi-
cant risk factor in females. When the fourth quartile of
GGT was compared with the first quartile, ORs for inci-
dence of diabetes were 1.58 (95% CI: 0.95-2.63) in males
and 1.85 (95% CI: 1.23-2.79) in females. Interactions of
GGT with alcohol intake status, BMI and WC were not
significant in either sex (data not shown).Discussion
This study examined the associations of serum liver en-
zymes on the incidence of type 2 diabetes in a prospective
study of a general Korean population. Our results suggest
that serum ALT and GGT were positively associated with
an increased risk of type 2 diabetes in both sexes, and no
interactions were seen between ALT or GGT and alcohol
intake status, BMI, or WC. After adjustment for potential
confounders, we found that elevated levels of ALT were
independently associated with type 2 diabetes in both
sexes, with an independent association for GGT only in
females.
In the present study, after adjusting for diabetes risk fac-
tors, the association between AST and incidence of dia-
betes was not significant in either sex. Our results are
consistent with those reported by Nakanishi et al. [21],
who found no association of AST with diabetes risk after
adjustment for age, family history of diabetes, BMI, alco-
hol intake, cigarette smoking, physical activity, systolic
blood pressure, lipid profile, fasting glucose, and white
blood cell count in a study of male Japanese office
workers. In contrast, in the prospective The Insulin Resist-
ance Atherosclerosis Study, Hanley et al. [5] reported that
AST independently predicted type 2 diabetes after adjust-
ment for covariates, including metabolic syndrome
Table 4 Adjusted odds ratio (95% confidence interval) for 4-years incidence of type 2 diabetes according to quartile
groups of liver enzymes (AST, ALT, and GGT) at baseline in females
Q1 Q2 Q3 Q4 P for trend
AST (units/l) ≤18 19 to 21 22 to 25 ≥26
Cases/persons at risk 74/983 58/1,066 86/1,187 95/1,104
Model 1 1 0.69 (0.48-0.98) 0.92 (0.67-1.28) 1.11 (0.80-1.52) 0.212
Model 2 1 0.66 (0.46-0.95) 0.87 (0.62-1.22) 0.99 (0.71-1.38) 0.567
Model 3 1 0.72 (0.49-1.05) 0.88 (0.62-1.25) 1.01 (0.72-1.43) 0.562
Model 4 1 0.67 (0.45-0.99) 0.83 (0.57-1.12) 0.95 (0.66-1.37) 0.783
ALT (units/l) ≤13 14 to 16 17 to 21 ≥22
Cases/persons at risk 56/1,199 52/994 77/1,003 128/1,127
Model 1 1 1.12 (0.76-1.65) 1.69 (1.18-2.40) 2.65 (1.91-3.67) <0.001
Model 2 1 0.99 (0.67-1.47) 1.40 (0.97-2.01) 1.86 (1.32-2.61) <0.001
Model 3 1 0.97 (0.64-1.48) 1.38 (0.94-2.02) 1.86 (1.31-2.65) <0.001
Model 4 1 0.86 (0.56-1.32) 1.23 (0.83-1.83) 1.49 (1.03-2.16) 0.006
GGT (units/l) ≤12 13 to 15 16 to 21 ≥22
Cases/persons at risk 45/1,248 42/882 85/1,076 141/1,117
Model 1 1 1.35 (0.88-2.07) 2.30 (1.59-3.33) 3.88 (2.74-5.49) <0.001
Model 2 1 1.14 (0.74-1.77) 1.73 (1.18-2.54) 2.69 (1.86-3.89) <0.001
Model 3 1 1.11 (0.70-1.76) 1.60 (1.06-2.39) 2.45 (1.66-3.61) <0.001
Model 4 1 0.97 (0.60-1.55) 1.27 (0.83-1.94) 1.85 (1.23-2.79) <0.001
Model 1: adjusted for age.
Model 2: Model 1 plus body mass index, waist circumference, total cholesterol, HDL-cholesterol, log-triglyceride, alcohol intake status, smoking status, physical
activity, and follow-up period.
Model 3: Model 2 plus log-CRP.
Model 4: Model 3 plus fasting glucose and HOMA.
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lin response, and CRP. The OR of type 2 diabetes for the
highest versus the lowest quartiles was 1.98 (95% CI: 1.23-
3.17). Although AST is a marker of hepatocellular health,
it is a less specific marker of liver function than ALT and
GGT [4]. Therefore, AST may be a less specific marker of
liver pathology related to development of type 2 diabetes.
Some prospective studies [5,8,10,11,13,14,24] have re-
ported that higher ALT concentrations predicted devel-
opment of type 2 diabetes. Our data also indicated that
ALT was an independent association in both sexes after
adjusting for other diabetes risk factors. In the late
1980s, Ohlson et al. [25] reported that baseline ALT was
a predictor of the incidence of type 2 diabetes after
13.5 years of follow-up in a cohort of 766 Swedish males,
with a significant fourfold increased risk for males in the
upper quintile compared to the lowest quintile.
Serum GGT has been widely used as an index of liver
dysfunction and as a biological marker of alcohol abuse
[17,21,26]. Most previous studies [3,4,6,7,10,12,14,16-20]
reported an association of GGT concentrations with the
incidence of type 2 diabetes, and our results are in
agreement with these findings. A 4-year follow-up pro-
spective cohort study in a Korean population [4] showed
a strong dose–response relationship between the serumGGT concentration at baseline and the incidence of type
2 diabetes. However, two studies reported no association
of GGT concentration with the development of type 2
diabetes [8,25]. In a longitudinal study of Pima Indians
[8], despite a strong correlation between ALT and GGT
concentrations, only ALT was positively associated with
the risk of type 2 diabetes. In the Pima Indian study, al-
cohol consumption was not evaluated, which could have
obscured the association between GGT and development
of type 2 diabetes. In our study, as in others, the associ-
ation of GGT with the incidence of type 2 diabetes was
independent of alcohol consumption [3,4,6,17,18,21].
Although the mechanism underlying the associations
between liver enzymes and incidence of type 2 diabetes
remains unclear, some possibilities can be considered.
One is that increased serum AST, ALT, and GGT levels
reflect an excess deposit of fat in the liver, a condition
known as non-alcoholic fatty liver disease (NAFLD).
NAFLD is considered a hepatic manifestation of meta-
bolic syndrome, which refers to a cluster of cardiovascu-
lar risk factors associated with insulin resistance,
including central obesity, hypertension, dyslipidemia, and
type 2 diabetes [27]. NAFLD, which is closely related to
obesity and visceral fat deposition, is now regarded as a
feature of insulin resistance syndrome [2], and visceral
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risk of type 2 diabetes [28]. Excess visceral fat accumula-
tion may be causally related to features of insulin resist-
ance as well as to high plasma levels of insulin and
glucose [29,30]. Overt diabetes is thought to be preceded
by a long period of insulin resistance, during which blood
glucose is maintained at a near-normal level by compen-
satory hyperinsulinemia [31]. In this study, ALT concen-
trations were independently associated with the incidence
of type 2 diabetes in both sexes, after adjusting for
HOMA as a marker of insulin resistance and fasting glu-
cose, whereas GGT was independently associated only in
females.
A second possibility is that GGT plays an important
role in antioxidant systems, with the primary function of
maintaining intracellular glutathione levels, a major intra-
cellular antioxidant defense for the cell [32-34]. Increased
oxidative stress contributes to the development and pro-
gression of diabetes [35,36] and chronic oxidative stress
results in decreased responsiveness to insulin, ultimately
leading to type 2 diabetes [30]. Although the mechanism
remains largely unknown, there is clear evidence that cel-
lular GGT concentration is closely related to oxidative
stress indicators in vivo [37-39]. Inflammation has also
been recognized as a manifestation of oxidative stress,
and all pathways that generate mediators of inflamma-
tion, such as adhesion molecules and interleukins, are in-
duced by oxidative stress [40]. Several prospective studies
have demonstrated that elevated CRP levels were signifi-
cantly predictive of risk of type 2 diabetes [41-46].
Changes in inflammation that occur through oxidative
stress are assumed to be a common step in the pathogen-
esis of type 2 diabetes. In the present study, after
adjusting for CRP as a marker of inflammation and/or
oxidative stress, GGT was found to be a significantly as-
sociated with the incidence of diabetes in both sexes.
These results suggested that the association was inde-
pendent of inflammation and oxidative stress.
The present study had the following limitation. We
were unable to complete follow-up examinations for all
participants who were still alive at the time of re-
examination, which may have introduced a selection bias.
The strengths of this study relate primarily to its pro-
spective design, with inclusion of a large sample size and
availability of data on lifestyles and diabetes risk factors.
Second, in contrast to most other prospective studies, in
which the diagnosis of diabetes was based only on self-
reporting, the diagnosis of diabetes in the present study
was based on both self-reporting and biological markers.
Third, we used relevant information to exclude subjects
with various etiologies of liver pathology, such as viral
hepatitis, liver cirrhosis, and liver cancer. Fourth, our
study considered the HOMA index, which is a well-
validated method for measurement of insulin resistanceand has shown a moderate-to-strong correlation (0.58 to
0.88) with reference techniques, such as the euglycemic
clamp [47].
Conclusions
In conclusion, in this prospective study, over a median
period of 4.2 years and after adjusting for potential con-
founders, elevated serum ALT concentrations in both
sexes and GGT only in females were independently as-
sociated with type 2 diabetes. The associations between
these enzymes and incidence of type 2 diabetes were in-
dependent of insulin resistance, inflammation and/or
oxidative stress markers. Although the mechanisms
underpinning these associations require further investi-
gation, these results support the hypothesis that the liver
is important in the pathogenesis of type 2 diabetes and
that hepatic enzymes may be useful additional markers
of subjects at high risk for development of diabetes.
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